Geode Capital Management LLC Acquires 217,308 Shares of Replimune Group, Inc. (NASDAQ:REPL)

Geode Capital Management LLC grew its position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 17.9% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,428,301 shares of the company's stock after purchasing an additional 217,308 shares during the period. Geode Capital Management LLC owned approximately 2.09% of Replimune Group worth $15,657,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in REPL. Point72 DIFC Ltd acquired a new position in Replimune Group in the second quarter worth $57,000. Arizona State Retirement System bought a new position in Replimune Group during the 2nd quarter valued at $108,000. Quest Partners LLC raised its position in Replimune Group by 30.4% in the second quarter. Quest Partners LLC now owns 13,510 shares of the company's stock worth $122,000 after acquiring an additional 3,150 shares in the last quarter. Erste Asset Management GmbH bought a new stake in shares of Replimune Group in the 3rd quarter worth approximately $133,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of Replimune Group by 82.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,140 shares of the company's stock worth $144,000 after acquiring an additional 5,926 shares in the last quarter. Institutional investors and hedge funds own 92.53% of the company's stock.

Replimune Group Stock Performance

REPL traded up $0.07 on Monday, reaching $12.33. The company had a trading volume of 507,379 shares, compared to its average volume of 1,041,018. Replimune Group, Inc. has a fifty-two week low of $4.92 and a fifty-two week high of $17.00. The company's fifty day moving average is $12.41 and its 200 day moving average is $10.93. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11. The stock has a market cap of $843.58 million, a P/E ratio of -4.04 and a beta of 1.26.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.07. As a group, analysts predict that Replimune Group, Inc. will post -2.91 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. HC Wainwright reissued a "buy" rating and set a $17.00 target price on shares of Replimune Group in a research note on Friday, November 22nd. BMO Capital Markets boosted their target price on shares of Replimune Group from $14.00 to $18.00 and gave the stock an "outperform" rating in a research report on Friday, November 22nd. JPMorgan Chase & Co. increased their price objective on Replimune Group from $14.00 to $17.00 and gave the company an "overweight" rating in a report on Tuesday, September 24th. Finally, Jefferies Financial Group boosted their price objective on Replimune Group from $16.00 to $19.00 and gave the stock a "buy" rating in a research report on Wednesday, December 4th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Replimune Group currently has an average rating of "Buy" and a consensus price target of $17.29.

Insider Activity at Replimune Group

In other Replimune Group news, CEO Sushil Patel sold 10,000 shares of the business's stock in a transaction on Monday, December 16th. The shares were sold at an average price of $12.42, for a total transaction of $124,200.00. Following the completion of the sale, the chief executive officer now owns 202,014 shares in the company, valued at approximately $2,509,013.88. The trade was a 4.72 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Konstantinos Xynos sold 7,246 shares of Replimune Group stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the transaction, the insider now directly owns 109,885 shares in the company, valued at approximately $1,184,560.30. The trade was a 6.19 % decrease in their position. The disclosure for this sale can be found here. 8.80% of the stock is currently owned by company insiders.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.